ArticleCell communication and signaling : CCS2026
Targeting TYRO3 attenuates apoptotic cell-driven cancer stemness in triple negative breast cancer.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApoptosis is a prevalent feature of the tumor microenvironment, driven not only by the rapid cellular turnover of high-grade cancers but also by chemotherapeutic agents. Although accumulating apoptotic cells can paradoxically support cancer cell survival and contribute to tumor recurrence, the roles of apoptotic cells in triple-negative breast cancer (TNBC) have not been elucidated. TYRO3, a receptor tyrosine kinase frequently overexpressed in cancers, plays a pivotal role in malignant progression. Here, we demonstrate that aggressive breast cancer cells exploit TYRO3 as a phosphatidylserine (PS)–sensing receptor to interact with apoptotic cells.
methodsWe investigated whether apoptotic cell–induced TYRO3 activation promotes cancer stemness. Expression of stemness markers NANOG and OCT4 was evaluated by immunoblottings and quantitative polymerase-chain-reaction, and spheroid formation assays were performed to functionally validate stemness. YAP nuclear translocation upon TYRO3 activation was assessed by nuclear fractionation, confocal microscopy, and dual-luciferase reporter assay. To validate the functional role of the TYRO3/YAP signaling axis, TYRO3 and YAP knockdown models were established by CRISPR/Cas9 or retroviral system. The anti-tumor efficacy of KRCT87, a selective TYRO3 inhibitor, was assessed in mouse models of tumor recurrence and tumor formation.
resultsApoptotic cells activated TYRO3 in aggressive breast cancer cells, enhancing stem-like properties and promoting tumor recurrence. Co-culture with apoptotic cells enhanced spheroid formation and upregulated stemness markers in TNBC cells, which were abolished by TYRO3 knockdown. Mechanistically, TYRO3 activation led to YAP nuclear translocation, which was responsible for stemness induction, as YAP knockdown suppressed this effect. In vivo xenograft studies demonstrated that TYRO3 inhibition suppressed tumor recurrence and apoptotic cells-induced tumor formation.
conclusionsOur findings indicate that apoptotic cells in the tumor microenvironment enhance cancer cell stemness and facilitate recurrence through TYRO3 activation. Neoadjuvant treatment with a TYRO3 inhibitor may represent a promising strategy to prevent breast cancer relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.